IGHVII-40-1: A Potential Drug Target Or Biomarker (G28368)

Target Name: IGHVII-40-1

NCBI ID: G28368

IGHVII-40-1

Other Name(s): immunoglobulin heavy variable (II)-40-1 (pseudogene) | 4-40.1P | IGHVII401 | Immunoglobulin heavy variable (II)-40-1 (pseudogene)

IGHVII-40-1: A Potential Drug Target Or Biomarker

IGHVII-40-1 (Immunoglobulin Heavy Variable (II)-40-1 (pseudogene)) is a human gene that encodes a type of antibody known as IgG. It is a single-chain variable region antibody that is one of the five classes of antibodies produced by B cells in the human body. IgG antibodies are the most abundant type of antibody in the bloodstream and are responsible for protecting the body against a wide range of pathogens, including bacteria, viruses, and parasites.

IGHVII-40-1 (pseudogene) is a stretch of DNA that is located on chromosome 17. It is a pseudogene, which means that it is a non-functional copy of a gene that has been transcribed but does not produce any functional RNA or protein. The IGHVII-40-1 (pseudogene) is also known as the P19 gene.

IGHVII-40-1 (pseudogene) is of interest as a potential drug target or biomarker because of its role in the immune system. The immune system is a critical part of the body's defense against infection and disease, and it is composed of a variety of different cell types and molecules. The IGHVII-40-1 (pseudogene) is one of the molecules that is involved in the production of antibodies, which are critical for protecting the body against pathogens.

Studies have shown that IGHVII-40-1 (pseudogene) is expressed in many different tissues and cells in the body, including the bone marrow, spleen, thymus, and the gut. It is also shown to be involved in the development and maintenance of the immune system.

One of the key features of IGHVII-40-1 (pseudogene) is its role in the production of antibodies. IgG antibodies are the most abundant type of antibody in the bloodstream, and they are produced by B cells in response to the presence of a pathogen or other antigen. The IGHVII-40-1 (pseudogene) is involved in the production of these antibodies by helping to regulate the activity of the B cell.

Another function of IGHVII-40-1 (pseudogene) is its role in the regulation of the immune response. IGHVII-40-1 (pseudogene) has been shown to play a role in the development and maintenance of tolerance, which is the ability of the immune system to distinguish between self and non-self and to avoid attacking the body's own tissues.

IGHVII-40-1 (pseudogene) may also be a potential biomarker for some diseases. For example, IGHVII-40-1 (pseudogene) has been shown to be decreased in individuals with autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Additionally , IGHVII-40-1 (pseudogene) has been shown to be increased in individuals with certain types of cancer, which may indicate that it is involved in the immune response to these diseases.

In addition to its role in the immune system, IGHVII-40-1 (pseudogene) may also be of interest as a potential drug target. For example, IGHVII-40-1 (pseudogene) has been shown to be involved in the production of antibodies, which are a key target for many drugs used in immunosuppressive treatments. Additionally, IGHVII-40-1 (pseudogene) may also be a potential target for drugs used to stimulate the immune system, such as cancer vaccines.

Overall, IGHVII-40-1 (pseudogene) is a fascinating molecule that is involved in many different aspects of the immune system. Its role in the production of antibodies and its involvement in the regulation of the immune response make it of interest as a potential drug target or biomarker. Further research is needed to fully understand the functions of IGHVII-40-1 (pseudogene) and its potential uses in medicine.

Protein Name: Immunoglobulin Heavy Variable (II)-40-1 (pseudogene)

The "IGHVII-40-1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGHVII-40-1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets